HK1204998A1 - Combinations of histone deacetylase inhibitor and pazopanib and uses thereof - Google Patents

Combinations of histone deacetylase inhibitor and pazopanib and uses thereof Download PDF

Info

Publication number
HK1204998A1
HK1204998A1 HK15105968.0A HK15105968A HK1204998A1 HK 1204998 A1 HK1204998 A1 HK 1204998A1 HK 15105968 A HK15105968 A HK 15105968A HK 1204998 A1 HK1204998 A1 HK 1204998A1
Authority
HK
Hong Kong
Prior art keywords
abexinostat
salt
pazopanib
cancer
hydrochloride
Prior art date
Application number
HK15105968.0A
Other languages
English (en)
Chinese (zh)
Inventor
‧巴拉蘇布拉馬尼安
S‧巴拉苏布拉马尼安
‧莫迪
T‧D‧莫迪
Original Assignee
药品循环有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 药品循环有限责任公司 filed Critical 药品循环有限责任公司
Publication of HK1204998A1 publication Critical patent/HK1204998A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15105968.0A 2012-02-17 2013-02-15 Combinations of histone deacetylase inhibitor and pazopanib and uses thereof HK1204998A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261600491P 2012-02-17 2012-02-17
US61/600,491 2012-02-17
US201261602544P 2012-02-23 2012-02-23
US61/602,544 2012-02-23
PCT/US2013/026462 WO2013123413A2 (en) 2012-02-17 2013-02-15 Combinations of histone deacetylase inhibitor and pazopanib and uses thereof

Publications (1)

Publication Number Publication Date
HK1204998A1 true HK1204998A1 (en) 2015-12-11

Family

ID=48984895

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105968.0A HK1204998A1 (en) 2012-02-17 2013-02-15 Combinations of histone deacetylase inhibitor and pazopanib and uses thereof

Country Status (12)

Country Link
US (1) US20150335609A1 (enExample)
EP (1) EP2814493A4 (enExample)
JP (1) JP2015507020A (enExample)
KR (1) KR20140129164A (enExample)
CN (1) CN104244952A (enExample)
AU (1) AU2013221298A1 (enExample)
CA (1) CA2864736A1 (enExample)
HK (1) HK1204998A1 (enExample)
MX (1) MX2014009892A (enExample)
RU (1) RU2014137190A (enExample)
SG (1) SG11201404888SA (enExample)
WO (1) WO2013123413A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160303231A1 (en) * 2013-12-11 2016-10-20 Robert Iannone Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
WO2017053823A1 (en) * 2015-09-25 2017-03-30 Pharmacyclics Llc Treatment using hdac inhibitors and immunotherapy
US11229657B2 (en) * 2017-04-21 2022-01-25 Lunella Biotech, Inc. Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy
JP7227777B2 (ja) * 2019-02-04 2023-02-22 キヤノン株式会社 撮像装置
KR20220018727A (ko) 2020-08-07 2022-02-15 계명대학교 산학협력단 파조파닙 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 비만 예방 또는 치료용 조성물
WO2022125551A1 (en) * 2020-12-07 2022-06-16 Hht Foundation International, Inc. Method of treating hereditary hemorrhagic telangiectasia using pazopanib

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102304110A (zh) * 2003-04-07 2012-01-04 Axys药物公司 作为治疗剂的异羟肟酸酯
EP1755394A4 (en) * 2004-04-16 2009-08-05 Smithkline Beecham Corp METHOD OF TREATING CANCER
DK1954281T3 (da) * 2005-11-29 2011-05-16 Glaxosmithkline Llc Fremgangsmåde til cancerbehandling
KR20110084533A (ko) * 2008-12-15 2011-07-25 일라이 릴리 앤드 캄파니 암의 치료를 위한 엔자스타우린
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
UY33367A (es) * 2010-05-05 2011-10-31 Glaxo Wellcome Mfg Pte Ltd Composiciones farmacéuticas y métodos para su elaboración
CN103476413B (zh) * 2011-01-26 2016-03-16 葛兰素史密斯克莱知识产权有限公司 组合

Also Published As

Publication number Publication date
CN104244952A (zh) 2014-12-24
WO2013123413A2 (en) 2013-08-22
EP2814493A4 (en) 2015-07-22
MX2014009892A (es) 2015-02-12
SG11201404888SA (en) 2014-09-26
AU2013221298A1 (en) 2014-08-28
US20150335609A1 (en) 2015-11-26
JP2015507020A (ja) 2015-03-05
CA2864736A1 (en) 2013-08-22
RU2014137190A (ru) 2016-04-10
EP2814493A2 (en) 2014-12-24
KR20140129164A (ko) 2014-11-06

Similar Documents

Publication Publication Date Title
US10105552B2 (en) Formulations of histone deacetylase inhibitor and uses thereof
JP6330118B2 (ja) ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用
HK1204998A1 (en) Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
CN109069410A (zh) 用于治疗血液恶性肿瘤和实体瘤的idh1抑制剂
JP2022524424A (ja) 向上したバイオアベイラビリティを有する化合物形態及びその製剤
EP3993809B1 (en) System for enhancing therapeutic compliance of the anti-cancer compound e7766
RU2820595C2 (ru) Система для повышения степени соблюдения терапевтической схемы с противораковым соединением e7766
HK1200095B (en) Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
US20190160054A1 (en) Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer